New hope for kidney disease: drug trial targets IgA nephropathy
NCT ID NCT05016323
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 26 times
Summary
This study tested an experimental drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine and protect kidney function better than a placebo. Participants took capsules for a period, and researchers measured changes in urine protein and kidney filtration rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
Conditions
Explore the condition pages connected to this study.